Who has been buying Dongyang Life Insurance stock?

1 distinct insiders have filed 0 disclosed insider purchases in Dongyang Life Insurance (082640), most recently on 2026-01-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Dongyang Life Insurance have?

Dongyang Life Insurance has 0 buy-side and 1 sell-side disclosures on record, covering ₩103M ($71K) in total reported value, spanning 2024-01-23 to 2026-01-01.

Where does StockDrifts get Dongyang Life Insurance insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Dongyang Life Insurance 082640

Company

동양생명Dongyang Life Insurance

Insiders

Buys

Total Value

₩103M ($71K)

Avg Return

-10.04%

Last Filing

2026-01-01

Dongyang Life Insurance (082640) has 0 disclosed insider purchases and 1 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩103M ($71K) in reported transaction value. The earliest filing StockDrifts holds for Dongyang Life Insurance is dated 2024-01-23; the most recent is 2026-01-01. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -10.04%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-11	SELL	교환	김경원 Kim Kyung-won	Managing Director	-1.5K	₩8,250	+0.0%	₩13M ($9K)
2026-08-11	SELL	교환	황문경 Hwang Moon-kyung	Managing Director	-2.5K	₩8,250	+0.0%	₩22M ($15K)
2026-08-11	SELL	교환	서혜연 Hyeyeon Seo	Managing Director	-8.2K	₩8,250	+0.0%	₩71M ($50K)
2026-08-07	SELL	주식매수청구권 행사	최호준 Choi Hojun	Managing Director	-12.5K	₩8,250	+0.0%	₩117M ($81K)
2026-01-01	BUY	신규선임	황문경 Hwang Moon-kyung	Managing Director	2.5K	₩6,400	+21.6%	₩16M ($11K)
2026-01-01	BUY	신규선임	최호준 Choi Hojun	Managing Director	12.5K	₩6,400	+21.6%	₩80M ($56K)
2025-07-01	BUY	장외매수	우리금융지주 Woori Financial Group	-	121.6M	₩6,870	+13.3%	₩835.2B ($580.0M)
2025-07-01	BUY	신규선임	이기정 Lee Ki-jeong	Acting executive duties	4.3K	₩6,870	+13.3%	₩30M ($21K)
2025-07-01	BUY	신규선임	구영석 Koo Young-seok	Compliance Manager	8.9K	₩6,870	+13.3%	₩61M ($43K)
2025-07-01	SELL	장외매도	DajiaLifeInsuranceCo.,Ltd.	-	-67.8M	₩6,870	-13.3%	₩465.6B ($323.4M)
2025-07-01	SELL	장외매도	AnbangGroupHoldingsCo.Limited	-	-53.8M	₩6,870	-13.3%	₩369.5B ($256.6M)
2025-06-19	SELL	Market Sell	곽경문 Kwak Gyeong-moon	Assistant Managing Director	-14.5K	₩7,070	-10.0%	₩103M ($71K)
2025-01-23	BUY	PROGRAM	정원교 garden bridge	Treatment for directors	1.0K	₩4,660	+67.0%	₩5M ($3K)
2025-01-23	BUY	PROGRAM	홍제민 Hong Je-min	Treatment for directors	1.1K	₩4,660	+67.0%	₩5M ($3K)
2025-01-23	BUY	PROGRAM	김경원 Kim Kyung-won	Treatment for directors	1.5K	₩4,660	+67.0%	₩7M ($5K)
2025-01-23	BUY	PROGRAM	이호태 Lee Ho-tae	Assistant Managing Director	3.0K	₩4,660	+67.0%	₩14M ($10K)
2025-01-23	BUY	PROGRAM	원진희 Jinhee Won	Managing Director	8.4K	₩4,660	+67.0%	₩39M ($27K)
2025-01-23	BUY	PROGRAM	서혜연 Hyeyeon Seo	Managing Director	1.2K	₩4,660	+67.0%	₩6M ($4K)
2025-01-23	BUY	PROGRAM	Jin, Xuefeng	Managing Director	11.4K	₩4,660	+67.0%	₩53M ($37K)
2025-01-23	BUY	PROGRAM	천수일 Cheon Soo-il	Assistant Managing Director	3.4K	₩4,660	+67.0%	₩16M ($11K)
2025-01-23	BUY	PROGRAM	안준영 Junyoung Ahn	Assistant Managing Director	5.1K	₩4,660	+67.0%	₩24M ($17K)
2025-01-23	BUY	PROGRAM	이준희 Junhee Lee	Managing Director	4.9K	₩4,660	+67.0%	₩23M ($16K)
2025-01-23	BUY	PROGRAM	곽경문 Kwak Gyeong-moon	Assistant Managing Director	4.0K	₩4,660	+67.0%	₩19M ($13K)
2025-01-23	BUY	PROGRAM	이문구 Lee phrase	CEO	12.1K	₩4,660	+67.0%	₩56M ($39K)
2025-01-23	BUY	PROGRAM	김정겸 Kim Jeong-gyeom	Treatment for directors	1.2K	₩4,660	+67.0%	₩6M ($4K)
2025-01-23	BUY	PROGRAM	이정훈 Jeonghoon Lee	Treatment for directors	841	₩4,660	+67.0%	₩4M ($3K)
2024-02-29	SELL	임원퇴임	JOU GWO DUAN	CEO	-59.6K	₩5,820	-33.7%	₩347M ($241K)
2024-02-07	BUY	PROGRAM	이준희 Junhee Lee	Assistant Managing Director	1.1K	₩5,110	+52.3%	₩6M ($4K)
2024-02-07	BUY	PROGRAM	안준영 Junyoung Ahn	Treatment for directors	694	₩5,110	+52.3%	₩4M ($2K)
2024-02-07	BUY	PROGRAM	김현전 Hyeonjeon Kim	vice president	9.8K	₩5,110	+52.3%	₩50M ($35K)
2024-02-07	BUY	PROGRAM	Jin, Xuefeng	Managing Director	6.5K	₩5,110	+52.3%	₩33M ($23K)
2024-02-07	BUY	PROGRAM	이문구 Lee phrase	vice president	6.0K	₩5,110	+52.3%	₩31M ($21K)
2024-02-07	BUY	PROGRAM	곽경문 Kwak Gyeong-moon	Treatment for directors	548	₩5,110	+52.3%	₩3M ($2K)
2024-02-07	BUY	PROGRAM	JOU GWO DUAN	CEO	4.6K	₩5,110	+52.3%	₩24M ($16K)
2024-02-07	BUY	PROGRAM	원진희 Jinhee Won	Managing Director	4.1K	₩5,110	+52.3%	₩21M ($15K)
2024-01-23	BUY	PROGRAM	김현전 Hyeonjeon Kim	vice president	15.1K	₩4,470	+74.0%	₩67M ($47K)

Frequently asked questions

Who has been buying Dongyang Life Insurance stock?: 1 distinct insiders have filed 0 disclosed insider purchases in Dongyang Life Insurance (082640), most recently on 2026-01-01. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Dongyang Life Insurance have?: Dongyang Life Insurance has 0 buy-side and 1 sell-side disclosures on record, covering ₩103M ($71K) in total reported value, spanning 2024-01-23 to 2026-01-01.
Where does StockDrifts get Dongyang Life Insurance insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Dongyang Life Insurance. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.